Washington Post, September 19, 2016. Despite lack of proof that the drug will help patients, FDA approves a controversial drug. NCHR president Diana Zuckerman asks “is there any drug the FDA won’t approve?”
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Feds to Crack Down on Those Who Fail to Report Clinical Trials
Politico Pro, September 16, 2016. Drug companies and research institutions will have to publicly report more clinical trial data, including results that show their products or experiments failed, under new policies rolled out Friday by HHS. But NCHR president criticizes their decision not to provide summaries of treatment results that patients can understand.
Read More »Doctors Downplaying Drug’s Suicide Risks Attract FDA’s Scrutiny
Bloomberg, September 13, 2016. The U.S. Food and Drug Administration has a message for doctors: The money you’re taking from pharmaceutical companies may be clouding your judgment. NCHR president Dr. Diana Zuckerman points out questions about the accuracy of safety data submitted by Pfizer about Chantix, the smoking cessation drug.
Read More »Medical Devices Approved Using Low-Quality Data Affect Medicare Costs
Bloomberg BNA, September 8, 2016. High-risk medical devices are sometimes approved using low-quality clinical data and this increases Medicare costs, a member of a Medicare congressional advisory panel said Sept. 8. “I agree completely” says Dr. Diana Zuckerman of NCHR
Read More »The ‘Grassroots Campaign’ for ‘Female Viagra’ Was Actually Funded by Its Manufacturer
New York Magazine’s The Cut, September 8, 2016. The “It” drug was Addyi, Sprout Pharmaceutical’s answer to low libido in women, approved by the FDA last August and now in the news for its low sales and for turning out to be a bit of a dud, effectiveness-wise.
Read More »